Biotech Values

[DewDiligence]

>> I am anxious to see how quickly GENR's AMD study enrolls...speaking of which where is the status of the Phase II IND? <<

I don’t think investors will be privy to the details of the IND until it is cleared by the FDA. At that time we should get a PR describing the trial design.

How fast will the trial enroll? It depends on the design because a placebo arm will slow enrollment somewhat. But I think it’s safe to say that, no matter what the design, the enrollment rate will be a lot better than the one patient per month that OXGN is now getting.